



Acarix changes Certified Adviser to Carnegie Investment Bank AB (publ)

Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).

Acarix has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on November 30, 2023.

For more information contact:

Fred Colen, acting CEO, email fred.colen@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Acarix changes Certified Adviser to Carnegie Investment Bank AB \(publ\)](#)